Dear Editor, Ozgen et al1 . recently conducted a study that focused on exploring the role of increased plasminogen activator inhibitor-1 (PAI-1) and vitronectin in gestational diabetes mellitus (GDM). GDM is a condition characterized by elevated blood sugar levels during pregnancy and is associated with various health risks. The study aimed to investigate the involvement of two key factors, namely, PAI-1 and vitronectin, in the pathophysiology of GDM. The research involved the analysis of blood samples and clinical data from pregnant women with and without GDM to compare the levels of PAI-1 and vitronectin. In this study, it was found that levels of vitronectin and PAI-1 were significantly elevated in the GDM group when compared to the control group. The findings of the study may have provided insights into the mechanisms underlying GDM, particularly the potential contribution of these two factors to the development and progression of the condition. Understanding the role of increased PAI-1 and vitronectin in GDM could have significant implications for the diagnosis, treatment, and management of this condition. It might open up avenues for targeted therapies or interventions aimed at mitigating the adverse effects of GDM and improving maternal and fetal health during pregnancy. However, some of the concerns outlined below require further clarification and explanation.